Multi-Lab Study Finds Few Lasting Psilocybin Effects
Readers following psilocybin research should note these results come from mice and found few lasting behavioral changes.
Updated on Nov. 2, 2026 in Mental Health

A coordinated study by five laboratories, including researchers from UC Berkeley, UCSF and Stanford, found that psilocybin produced no lasting behavioral changes in mice 24 hours after a single dose. The results were published in Nature Neuroscience.
Why it matters
Psilocybin has drawn wide interest as a possible treatment for depression and anxiety, so reproducible evidence about what it does and does not change matters for how seriously the field and the public should read early claims. The identical parallel design was intended to separate consistent effects from lab-specific noise.
This was a multi-laboratory study in which five labs ran identical experiments in mice and pooled their data. Because it was conducted in animals, its findings cannot be directly applied to human patients.
The players
University of California, Berkeley
A leading public research university whose researchers led the multi-lab psilocybin study.
University of California, San Francisco
A major academic medical center and research institution that contributed researchers to the psilocybin study.
Stanford University
A research university with a large neuroscience and psychiatry research presence that contributed researchers to the psilocybin study.
The details
Researchers tested psilocybin's behavioral effects across five labs using the same protocols, then combined the results. Mice showed heightened anxiety and avoidance, and reduced fear expression, within 10 minutes of dosing, but these immediate responses did not persist to 24 hours. The team also found no evidence that psilocybin reopened a critical period for social reward learning in adult mice, and no reproducible reduction in anxiety or depression-like behaviors.
Timeline
24 hours after a single dose: researchers measured no lasting behavioral changes in mice.
10 minutes after dosing: mice showed increased anxiety and reduced fear expression.
November 2, 2026: the findings were reported in coverage of the study.
Health Landscape
Psilocybin is being studied as a possible treatment for depression and anxiety, with human trials advancing alongside basic research. Multi-lab replication work like this helps separate reproducible effects from results that depend on a single laboratory's setup.
If you are following news about psilocybin for depression or anxiety, this study is a reminder that animal results and early findings do not yet translate into treatment recommendations. Anyone considering psychedelic-based approaches should discuss the current evidence and options with a qualified clinician.
The takeaway
Replication across multiple labs is what makes a finding trustworthy, and this study shows how much early psilocybin results can vary by method. When reading about new psychedelic research, look for whether results have been reproduced and whether the study was done in animals or people.
Further reading
For broader context on how researchers are testing treatments for mood and anxiety conditions, see Mental Health.
Source note: This article includes information reported by Drug Target Review.


